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Heparin and warfarin, a vitamin K antagonist, were first widely 
used to treat venous thromboembolic disease (VTED) in the early 
1940s. [1] Later low-molecular-weight heparin followed by a vitamin 
K antagonist became the recommended therapeutic regimen.[2] 
Vitamin K antagonists have also been the drugs of choice in preventing 
thrombo embolic events in patients with atrial fibrillation. The major 
problem with warfarin has been unpredictable pharmacodynamic and 
pharmacokinetic properties, including food and drug interactions, 
with resultant marked fluctuation in anticoagulation control in a 
significant number of patients. This, together with the large number 
of patients on long-term oral anticoagulation, has been the impetus for 
the development of oral alternatives by pharmaceutical companies.[3,4]
Direct oral anticoagulants (DOACs) target individual activated 
coagulation factors, and their pharmacological properties are detailed 
in Table 1. These agents have been investigated in multicentre trials 
to establish efficacy and safety in the treatment and prevention of 
venous thromboembolism in many clinical conditions (Tables 2 
and 3). The two agents registered in South Africa (SA) to date are 
rivaroxaban (Xarelto; Bayer), a direct factor Xa (FXa) inhibitor, and 
dabigatran (Pradaxa; Boehringer Ingelheim), a factor IIa (thrombin) 
inhibitor. Both these agents are currently registered in SA for the 
treatment and prevention of VTED, i.e. deep-vein thrombosis (DVT) 
and pulmonary embolism (PE), as well as for prevention of stroke and 
systemic embolism in patients with non-valvular atrial fibrillation.
Because up to 80% of the active component of dabigatran is excre-
ted renally, any renal impairment, especially in the elderly, can 
result in toxicity with resultant haemorrhage. Although the rate 
and severity of major haemorrhage were lower in trial patients on 
rivaroxaban than in those on standard therapy, overall haemorrhagic 
complications occurred with the same frequency.[4]
Studies have demonstrated DOACs to be effective and safe at fixed 
doses without laboratory activity monitoring. Evidence has shown 
that qualitative drug activity information seems to be adequate in 
most clinical situations. There are, however, specific situations where 
assessment of accurate drug activity levels may be required (Table 4).[5,6]
The lack of requirement for routine monitoring of DOACs is based 
on the assumed similarity in pharmacokinetic and pharmacodynamic 
responses between individuals with varying demographics, including 
age, race, gender, renal function and body mass index (BMI). It has, 
however, been estimated that the same dose of a DOAC can produce 
an up to 30% difference in thrombin generation inhibition.[7] There has 
been speculation that bleeding would be more likely in high responders 
and thrombosis more likely in low responders. Clinical trials usually 
exclude patients with impaired renal function, extremes of age (i.e. 
<18 and >65 years), those with an increased bleeding risk and those at 
the extremes of body weight. The lack of a need to monitor that was 
demonstrated in the trials may therefore not be applicable in real-life 
situations.
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Background. Low-molecular-weight heparin and vitamin K antagonists such as warfarin are the gold standard for prohylaxis and treatment of 
venous thromboembolic disease (VTED). Direct oral anticoagulants (DOACs) result in predictable anticoagulation with significantly reduced 
inter- and intra-patient variability. DOAC absorption is rapid, with a short half-life and relatively few drug interactions. DOACs are effective 
and safe at fixed doses without activity monitoring. However, specific situations may require assessment of accurate drug activity. Rivaroxaban, 
a DOAC targeting activated coagulation factor X (FXa), is registered for the prevention and treatment of VTED in South Africa.
Objectives. To establish a prophylactic rivaroxaban activity level range and determine any associations with clinical complications, viz. 
haemorrhage and/or thrombosis.
Methods. Samples from 115 orthopaedic patients were tested 3 hours after a prophylactic oral dose of 10 mg rivaroxaban with STAGO 
rivaroxaban anti-FXa reagent on an automated coagulation analyser. Patient demographics and clinical outcomes were documented.
Results. The mean rivaroxaban anti-FXa level was 105.7 ng/mL. Two patients developed adverse events on therapy. One patient had minor 
bleeding (menorrhagia) (drug activity level 288.7 ng/mL) and another a deep-vein thrombosis (drug activity level 34.7 ng/mL). Statistical 
analysis demonstrated an association between drug activity and advancing age (p=0.008), most apparent among those aged ≥65 years.
Conclusions. Measuring rivaroxaban activity levels may reduce uncertainty if treatment failure and complications occur. Patients aged 
≥65 years should be closely monitored. A local expected rivaroxaban activity level for patients on rivaroxaban prophylaxis has been established.
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A study by Reilly et al.[8] on the effect of 
dabigatran plasma concentrations showed 
that laboratory measurement of drug activity 
is important and suggests that testing will 
become more widespread in the future as 
doctors strive to reduce complications and 
improve efficacy. This study concluded 
that both ischaemic stroke and bleeding 
outcomes correlated with dabigatran plasma 
concentrations. It is therefore important for 
clinical laboratories to have the ability to 
measure drug activity rapidly.
Rivaroxaban exerts a direct anti-FXa activ-
ity in plasma. The rational choice to measure 
direct FXa-inhibitors is therefore an anti-FXa 
assay. A number of studies have concluded 
that anti-FXa chromogenic assays are more 
specific and sensitive than routine clotting 
test-based assays. In addition, there is a better 
correlation between plasma concentrations 
measured by liquid chromatography/mass 
spectrometry and levels estimated by anti-
FXa assays than those obtained using the 
routine prothrombin time (PT) assay. The 
rivaroxaban anti-FXa assay demonstrates an 
adequate linearity response to increasing con-
centrations of rivaroxaban. [9,10] Commercial 
reagents are available for measuring rivaroxa-
ban anti-FXa activity on routine automated 
coagulation analysers. It is essential for every 
laboratory to establish its own reference range 
in its patient-specific population and labora-
tory environment.[5,8]
Objectives
To establish an expected rivaroxaban activity 
level for patients on prophylactic doses of 
Table 1. Overview of DOACs registered in SA[3]
Rivaroxaban Dabigatran
Mechanism of action Direct FXa inhibitor Direct thrombin inhibitor
Route of administration Oral Oral (prodrug)
Fixed-dose administration Yes Yes
Onset of action Rapid (within 2 hours) Rapid (within 2 hours)
Pharmacokinetics: bioavailability after oral administration 60 - 86% ∼6% 
Half-life 7 - 11 hours 14 - 17 hours
Excretion Biliary/faecal (28%); renal (33% metabolised, 
33% excreted unchanged)
Renal (80%) 
Anticoagulant response Predictable Predictable
Routine coagulation monitoring needed No No
Food interactions Absorption moderately increased by food Delayed absorption with food
Drug interactions Ketoconazole, itraconazole, voriconazole, 
posaconazole, fluconazole, ritonavir, 
phenytoin, carbamazepine, phenobarbital, 
aspirin, NSAIDs, St John’s wort, rifampicin
NSAIDs, St John’s wort, rifampicin, 
verapamil, clarithromycin, 
amiodarone, verapamil, aspirin (with 
higher doses of dabigatran)
Risk of thrombocytopenia Minimal Minimal
NSAIDs = non-steroidal anti-inflammatory drugs.
Table 2. High-level summary rivaroxaban clinical trials
Clinical indication Trial name, year, n Treatments
Trial design, number of 
participating countries
VTED prophylaxis 
in total hip and knee 
arthroplasty
RECORD 1-3, 2008,
n=4 772 v. 4 809
Rivaroxaban 10 mg 
orally v. enoxaparin 
40 mg subcutaneously 
once daily
Parallel groups, double 
blind, 27 countries 
VTED treatment: 
DVT and PE
Einstein-DVT and 
PE, 2010/ 2012,
n=4 150 v. 4 131
Rivaroxaban 15 mg twice 
daily for 3 weeks, then 
20 mg daily v. standard 
therapy (enoxaparin 
followed by warfarin)
Parallel groups, open 
label, 38 countries
SPAF ROCKET-AF, 2010,
n=7 131 v. 7 133
Rivaroxaban 20 mg 
daily v. warfarin 
Parallel groups, double 
blind, 45 countries
n = number of patients on study drug v. number of patients on standard therapy; SPAF: stroke prevention in atrial fibrillation.
Table 3. High-level summary dabigatran clinical trials
Clinical indication Trial name, year, n Treatments
Trial design, number 
of participating 
countries
VTED prophylaxis 
in total hip 
arthroplasty 
RE-NOVATE, 2007,
n=2 184 v. 2 165
Dabigatran 150 or 
220 mg/d v.
enoxaparin 40 mg/d
Parallel groups,
double blind,
multiple countries
VTED treatment: 
DVT and PE
RE-COVER, 2009/2011, 
n=2 568 v. 2 560
Dabigatran 150 mg 
twice daily v. 
warfarin 
Parallel groups,
double blind,
31 countries
SPAF RE-LY, 2010,
n=12 257 v. 12 114
Dabigatran 110 
or 150 mg daily v. 
warfarin
Parallel groups,
open with blinded 
assessment,
44 countries
n = number of patients on study drug v. number of patients on standard therapy; SPAF = stroke prevention in atrial fibrillation.
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rivaroxaban as well as to assess any associat-
ion between clinical complications, viz. 
haemorrhage and/or thrombosis, and drug 
levels. 
Methods
This was a cross-sectional pilot study 
measuring rivaroxaban anti-FXa activity 
in orthopaedic patients admitted to a pri-
vate hospital in Gauteng Province, SA, for 
elective foot and ankle surgery. The study 
was conducted over a 9-month period 
between 2014 and 2015. Ethics approval was 
obtained from the Human Research Ethics 
Committee (Medical) of the University of the 
Witwatersrand, Johannesburg, and uncondi-
tional approval was given (ref. no. M131165).
Venous blood was collected from 115 con-
secutive orthopaedic patients post surgery, 
3  hours after administration of a prophylac-
tic oral dose of 10 mg rivaroxaban. Patient 
demographics (age, race, gender, BMI and 
estimated glomerular filtration rate (eGFR)) 
as well as clinical outcomes were docu-
mented. Blood samples were analysed with 
STAGO rivaroxaban anti-FXa reagent on 
an automated coagulation analyser after 
successful calibration and performance of 
controls. Drug activity was measured as anti-
FXa activity in ng/mL.
Statistical analysis
A descriptive analysis was conducted which 
included summary measures, i.e. mean and 
standard deviation (SD) for continuous 
varia bles such as age, BMI and eGFR. We 
also presented the mean (SD) for anti-FXa as 
an outcome variable. Frequency tabulations 
were also presented for categorical variables: 
gender, age group (<65 years and ≥65 years) 
and BMI (categorised into underweight, 
normal, overweight and obese).
An investigation of statistical associations 
between the outcome variable and demo-
graphic factors was performed using a t-test 
for comparing two groups and analysis of 
variance (ANOVA) where more than two 
groups were being compared. The tests were 
conducted at a 5% significance level. Further, 
a linear regression analysis was conducted 
through a univariate regression model. 
Factors found significant at a 20% level in 
the univariate analysis were then considered 
in the multiple linear regression analysis.
Results
A total of 115 patients, of whom 56 (48.7%) 
were female, were included (Table 5). The 
mean age was 54 years (SD 15), with 89 patients 
(77.4%) being <65 years of age. Ninety-nine 
patients (86.1%) were overweight (BMI >25), 
with 56 (56.6%) classified as obese. 
The mean rivaroxaban anti-FXa level in 
the study population 3 hours after receiving 
a 10 mg dose was 105.7 ng/mL (95% confi-
dence interval (CI) 94.9 - 116.6).
Two patients experienced adverse events 
on rivaroxaban therapy. A 43-year-old woman 
with normal renal function and an elevated 
BMI of 40 had minor bleeding (menorrhagia) 
without a decrease in haemo globin. Her riva-
roxaban level was 288.7 ng/mL. The second 
adverse event occurred in a 47-year-old man 
who developed a below-knee DVT. He had a 
normal BMI of 22, with a rivaroxa ban activity 
level of 34.7 ng/mL.
After considering significant factors at 
univariate level, the final multiple linear 
regression model demonstrated a statistically 
significant association between drug acti-
vity and advancing age (p=0.008), this 
being most apparent among patients aged 
≥65  years. Creatinine clearance as estimated 
by the eGFR, however, did not demonstrate a 
statistically significant association with drug 
level (p=0.100). There was no association 
between drug level and the other demographic 
variables, such as gender (p=0.283) and BMI 
(p=0.095) (Table 6). 
Conclusions
Commercial assays are available to measure 
rivaroxaban anti-FXa activity. The clinical 
application of rivaroxaban activity levels may 
reduce uncertainty in the event of treatment 
failure and bleeding complications. The 
mean rivaroxaban anti-FXa level in the 
study population 3 hours after receiving 
Table 4. Clinical situations in which the measurement of DOAC anticoagulant activity is 
potentially useful
When stable anticoagulation is achieved (1 - 2 weeks after initiation)
Before surgical or other invasive procedures 
Adverse events (haemorrhage or thrombosis)
Before and after introducing additional drugs which are known to interact
Extremes of body mass index
Suspected overdose
When bridging from one anticoagulant to another
To assess compliance
To exclude drug accumulation in the elderly
To assess pharmacological activity, i.e. quality control
In patients with renal or hepatic dysfunction
Table 5. Demographic and clinical 
characteristics of the patients (N=115)
Factor n (%)
Gender
Male 59 (51.3)
Female 56 (48.7)
Age (yr)
<65 89 (77.4)
≥65 26 (22.6)
BMI
Underweight 1 (0.9)
Normal 15 (13.0)
Overweight 43 (37.4)
Obese 56 (48.7)
eGFR (mL/min)
<60 9 (7.8)
≥60 106 (92.2)
Anti-FXa (ng/mL), mean (SD) 105.7 
(58.61)
Table 6. Associations between 
demographic and clinical characteristics 
and anti-FXa levels
Factor
Anti-FXa (ng/
mL), mean (SD) p-value
Gender
Male 100.54 (51.35)
Female 111.83 (65.32) 0.283
Age group (yr)
<65 98.09 (55.09)
≥65 132.14 (63.61) 0.009
BMI
Normal 83.54 (50.01)
Overweight 118.72 (59.80)
Obese 100.62 (58.12) 0.095
eGFR (mL/min)
<60 136.64 (52.14)
≥60 103.17 (58.60) 0.100
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a 10 mg dose was 105.7 ng/mL, with a range of 25.0 - 283.2. This 
preliminary pilot study demonstrated a statistically significant associ-
ation between advanced age and rivaroxaban activity levels, but no 
association with eGFR. Estimated creatinine clearance reflected by 
the eGFR is, however, not sensitive enough to detect deterioration in 
renal function, especially with advancing age.[11] Not only are elderly 
patients at an increased risk of venous thromboembolism, but they 
are also at an increased risk of bleeding. Increase bleeding risk in 
the elderly is related to comorbid diseases such as hypertension and 
malignancy, deteriorating renal function, polypharmacy and frailty 
with an increased risk of falls.[12,13] Although the significance of the 
increased rivaroxaban activity levels in the elderly is unknown, this 
study suggests that patients aged ≥65 years on therapy should be 
closely monitored. A local expected rivaroxaban activity level for 
patients on prophylactic therapy has been established.
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